Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA
Funding The preparation of this review was not supported by any external funding.
Authorship and conflict of interest Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Oritavancin, a long-acting lipoglycopeptide, is the first single-dose intravenous (IV) antibacterial therapy approved in the USA for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms. With its well-established antibacterial activity, efficacy and safety profiles, a new IV formulation of oritavancin (KIMYRSA™) has been developed to offer a more convenient treatment option for patients with ABSSSIs. Relative to the originally approved IV formulation of oritavancin (ORBACTIV®), the new IV formulation has better diluent compatibility, simpler preparation steps, a shorter infusion time of 1 h in a lower infusion volume of 250 mL. Approval was based on results of a phase 1 study in which pharmacokinetic similarity between the two IV formulations of oritavancin was demonstrated in patients with ABSSSIs. The tolerability profile of the new IV formulation of oritavancin revealed no new safety signals.
© Springer Nature Switzerland AG 2021